Australian biotech AdAlta (ASX: 1AD) and privately-owned German firm XL-protein GmbH have agreed a collaboration to develop a long acting form of AD-114, a new drug candidate for fibrosis therapy.
AD-114 is AdAlta’s lead i-body drug candidate being developed for idiopathic pulmonary fibrosis (IPF) and a variety of other fibrotic and inflammatory diseases.
"We aim to progress AD-114 towards the clinic by early 2018"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze